President Donald Trump’s administration announced that Medicare will pay reduced prices for 15 prescription drugs, including weight-loss and cancer medications.
On Tuesday, the Centers for Medicare & Medicaid Services revealed that the reduced drug prices are expected to save the government about $12 billion on Medicare spending compared with last year.
“President Trump directed us to stop at nothing to lower health care costs for the American people,” Health and Human Services Secretary Robert F. Kennedy, Jr. said in a news release. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.”
The new “maximum fair prices” for the drugs will take effect on January 1, 2027, raising the total number of medications with negotiated prices to 25 when added to the 10 announced by former President Joe Biden’s administration last year.
“This year’s results stand in stark contrast to last year’s,” CMS Administrator Mehmet Oz said. “Using the same process with a bolder direction, we have achieved substantially better outcomes for taxpayers.”
Among the drugs included in the program are weight-loss drugs Ozempic and Wegovy and cancer drugs Xtandi, Pomalyst, Ibrance.
The others are: Trelegy Ellipta, Ofev, Linzess, Calquence, Austedo and Austedo XR, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet and Janumet XR and Otezla.
.jpeg?w=390&resize=390,220&ssl=1 "Woman pleaded for help finding engagement ring lost while fishing for crabs. Then divers came to the rescue")
